Naldemedine is an opioid receptor antagonist . It is a modified form of Naltrexone to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation.
For the treatment of opioid-induced constipation .
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.